

---

**Product Data Sheet**

---

Product Name: SR121566A

Cat. No.: GC31993

**Chemical Properties**

Cas. No. 180144-61-0

SMILES O=C(O)CN1CCC(N(C2=NC(C3=CC=C(C(N)=N)C=C3)=CS2)CCC(O)=O)CC1Formula C<sub>20</sub>H<sub>25</sub>N<sub>5</sub>O<sub>4</sub>S M.Wt 431.51

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Protocol****Animal experiment:**

Male mice (26-30 g) are anesthetized, artificially ventilated, and placed on a heated jacket to control body temperature. A femoral vein is cannulated for i.v. injections. In thrombosis experiments, drugs including SR121566A are administered in 0.9% saline for intravenous studies (0.1 mL/30 g, 5 min before stimulation) and in water for oral studies (0.1 mL/30 g, 120 min before stimulation)[2].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

### References:

[1]. Herault JP et al. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. *Thromb Haemost.* 1998 Feb;79(2):383-8.

[2]. Lorrain J, et al. Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel. *J Pharmacol Exp Ther.* 2004 Apr;309(1):235-40.

### Background

SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of  $46 \pm 7.5$ ,  $56 \pm 6$  and  $42 \pm 3$  nM, respectively.

SR121566A leads to dose-dependent increases in TTO, a statistically significant increase being observed at the doses of 0.3 mg/kg (473%) and 30 mg/kg (771%), respectively[2].

[1]. Herault JP et al. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. *Thromb Haemost.* 1998 Feb;79(2):383-8. [2]. Lorrain J, et al. Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel. *J Pharmacol Exp Ther.* 2004 Apr;309(1):235-40.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA